Codice QR

KRAS Withdrawal in Cholangiocarcinoma Leads to Immune Infiltration and Tumor Regression

Abstract Cholangiocarcinoma (CCA) is a liver cancer subtype with poor survival rates. KRAS mutations are found in 15–40% of CCA, representing a new potential treatment target. Whether KRAS inhibition leads to CCA tumor regression is unknown, partly due to the lack of conditional animal models. A con...

Descrizione completa

Salvato in:
Autori principali: Youwei Qiao, Matthew F. Yee, Chaitanya N. Parikh, Boyang Ma, Yueying Cao, Yu‐Huan Shih, Joae Qiong Wu, Marcus Ruscetti, Shun‐Qing Liang, Wen Xue
Natura: Artigo
Lingua:Inglês
Pubblicazione: Wiley 2026-01-01
Serie:Advanced Science
Soggetti:
biliary malignancy
cholangiocarcinoma
KRAS inhibition
oncology
Accesso online:https://doi.org/10.1002/advs.202511312
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne!!

Documenti analoghi